Gapping down
In reaction to disappointing earnings/guidance: NOW -19.1%, OSIS -15%, SGI -13.5%, EBAY -12.8%, URI -12%, INVN -10.1%, JNPR -9.6%,OAS -8.8%, KEX -7.6%, ACAT -7.3%, CLB -7.1%, CLB -7.1%, DFS -6%, HOLX -4.7%, POT -4.2%, ABT -3.6%, CRR -3.3%, BX -2.7%, MO -2.7%,QCOM -2.6%, DB -2.4%, AN -2.4%, CELG -2.3%, VAR -1.9%, EXTR -1.8%, VRTX -1.4%, SWK -1.2%, CGI -0.9%, SHW -0.9%, DEO -0.8%, NG-0.7%, NOC -0.7%
Other news: INCY -11.2% ( stops phase 2 sub-study early after interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus regorafenib did not show a sufficient level of efficacy ), SGI -9.1% (announces universal shelf registration of up to $75 mln), FCX -3.7% (Moody's downgrades FCX's ratings, assigns B1 CFR; outlook negative), NVS -1.7% (in symp with peer Roche, which reported this morning in Europe), MOS -1.6% (in symp with POT),CS -1.5% (in symp with DB), BXLT -0.5% (prices offering of 37,573,040 shares of its common stock by Baxter (BAX) at $39.50 per share)
Analyst comments: X -1.3% (downgraded to Hold at Argus)
In reaction to disappointing earnings/guidance: NOW -19.1%, OSIS -15%, SGI -13.5%, EBAY -12.8%, URI -12%, INVN -10.1%, JNPR -9.6%,OAS -8.8%, KEX -7.6%, ACAT -7.3%, CLB -7.1%, CLB -7.1%, DFS -6%, HOLX -4.7%, POT -4.2%, ABT -3.6%, CRR -3.3%, BX -2.7%, MO -2.7%,QCOM -2.6%, DB -2.4%, AN -2.4%, CELG -2.3%, VAR -1.9%, EXTR -1.8%, VRTX -1.4%, SWK -1.2%, CGI -0.9%, SHW -0.9%, DEO -0.8%, NG-0.7%, NOC -0.7%
Other news: INCY -11.2% ( stops phase 2 sub-study early after interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus regorafenib did not show a sufficient level of efficacy ), SGI -9.1% (announces universal shelf registration of up to $75 mln), FCX -3.7% (Moody's downgrades FCX's ratings, assigns B1 CFR; outlook negative), NVS -1.7% (in symp with peer Roche, which reported this morning in Europe), MOS -1.6% (in symp with POT),CS -1.5% (in symp with DB), BXLT -0.5% (prices offering of 37,573,040 shares of its common stock by Baxter (BAX) at $39.50 per share)
Analyst comments: X -1.3% (downgraded to Hold at Argus)